Intellia TherapeuticsNTLA
NTLA
About: Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
Employees: 598
0
Funds holding %
of 7,296 funds
0
Analysts bullish %
of 7 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
13% more first-time investments, than exits
New positions opened: 51 | Existing positions closed: 45
9% more call options, than puts
Call options by funds: $7.04M | Put options by funds: $6.43M
0% more funds holding
Funds holding: 289 [Q4 2024] → 290 (+1) [Q1 2025]
0.34% more ownership
Funds ownership: 97.45% [Q4 2024] → 97.79% (+0.34%) [Q1 2025]
0% more funds holding in top 10
Funds holding in top 10: 2 [Q4 2024] → 2 (+0) [Q1 2025]
2% less repeat investments, than reductions
Existing positions increased: 93 | Existing positions reduced: 95
38% less capital invested
Capital invested by funds: $1.16B [Q4 2024] → $720M (-$438M) [Q1 2025]
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$10
20%
upside
Avg. target
$34
309%
upside
High target
$68
718%
upside
7 analyst ratings
5 positive
71%
2 neutral
29%
0 negative
0%
Canaccord Genuity Whitney Ijem | 550%upside $54 | Buy Maintained | 3 Jun 2025 |
HC Wainwright & Co. Mitchell Kapoor | 261%upside $30 | Buy Reiterated | 29 May 2025 |
Wedbush David Nierengarten | 20%upside $10 | Neutral Reiterated | 19 May 2025 |
Guggenheim Debjit Chattopadhyay | 442%upside $45 | Buy Maintained | 12 May 2025 |
Citigroup David Lebowitz | 20%upside $10 | Neutral Maintained | 9 May 2025 |
Financial journalist opinion
Based on 9 articles about NTLA published over the past 30 days
Neutral
GlobeNewsWire
1 week ago
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., June 05, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that on June 1, 2025, it awarded an inducement grant to six new employees under Intellia's 2024 Inducement Plan as a material inducement to employment.
Positive
Zacks Investment Research
1 week ago
How Much Upside is Left in Intellia Therapeutics (NTLA)? Wall Street Analysts Think 398.31%
The consensus price target hints at a 398.3% upside potential for Intellia Therapeutics (NTLA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Negative
Zacks Investment Research
2 weeks ago
NTLA Stock Down as Patient Faces Adverse Event in Gene Therapy Study
Intellia stock tanks after a patient in its phase III study evaluating gene therapy candidate nex-z in ATTR-CM experiences serious liver enzyme elevation.
Negative
Benzinga
2 weeks ago
Intellia Therapeutics' Rare Heart Disease Candidate Reports Liver Enzyme Spike In Phase 3 Trial, But Stays On Course
Intellia Therapeutics Inc NTLA said on Wednesday that a single, recent, asymptomatic patient has had grade 4 (severe) liver transaminase elevations (liver enzymes) based on laboratory tests in its Phase 3 MAGNITUDE study.
Negative
MarketBeat
3 weeks ago
Analysts Think These Stocks Could More Than Double in Value
Persistent volatility has plagued the S&P 500 for much of 2025, prompting widespread caution among many investors amid the uncertainties of trade battles, tariffs, domestic policy, and more. Investors might remember that many of the biggest rallies take place during these volatile periods, and there may be potential to win big gains for those with at least a moderate tolerance for risk.
Neutral
GlobeNewsWire
3 weeks ago
INTELLIA ALERT: Bragar Eagel & Squire, P.C. is Investigating Intellia Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
NEW YORK, May 22, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Intellia Therapeutics, Inc. (NASDAQ:NTLA) on behalf of long-term stockholders following a class action complaint that was filed against Intellia on February 11, 2025 with a Class Period from July 30, 2024 to January 8, 2025. Our investigation concerns whether the board of directors of Intellia have breached their fiduciary duties to the company.
Neutral
Zacks Investment Research
3 weeks ago
3 Top Genomics Stocks to Add to Your Portfolio in 2025
Investors interested in the Genomics and Synthetic Biology theme may consider adding these three stocks to their portfolio - Intellia Therapeutics (NTLA), uniQure (QURE) and Verve Therapeutics (VERV).
Positive
Seeking Alpha
3 weeks ago
I Missed The Quantum Rally - I Won't Miss The Next One
Here's the next batch of weird science stocks that have market darling potential. I'm tracking five meme-worthy, deep science sectors: brain-computer interfaces, CRISPR/gene editing, organoids, programmable cell therapy, and room-temperature superconductors. Monitor each sector's stocks poised to soar if a major tech player announces a breakthrough.
Neutral
GlobeNewsWire
3 weeks ago
Intellia Announces Positive Two-Year Follow-Up Data from Ongoing Phase 1 Study of Nexiguran Ziclumeran (nex-z), in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy at Peripheral Nerve Society Annual Meeting
CAMBRIDGE, Mass., May 18, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced positive two-year follow-up data from the ongoing Phase 1 trial of investigational nexiguran ziclumeran (nex-z) for the treatment of hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN). Results were shared in an oral presentation on Sunday, May 18 at the 2025 Peripheral Nerve Society (PNS) Annual Meeting in Edinburgh, United Kingdom. The Phase 3 MAGNITUDE-2 trial design of nex-z in ATTRv-PN was also exhibited in a poster presentation.
Positive
Zacks Investment Research
1 month ago
Wall Street Analysts See a 408.63% Upside in Intellia Therapeutics (NTLA): Can the Stock Really Move This High?
The mean of analysts' price targets for Intellia Therapeutics (NTLA) points to a 408.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Charts implemented using Lightweight Charts™